Co-Authors
This is a "connection" page, showing publications co-authored by Paul Bastard and Helen Su.
Connection Strength
1.294
-
Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci Immunol. 2021 08 19; 6(62).
Score: 0.241
-
Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1. J Exp Med. 2021 07 05; 218(7).
Score: 0.239
-
Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine. J Exp Med. 2021 04 05; 218(4).
Score: 0.235
-
Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020 10 23; 370(6515).
Score: 0.226
-
X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19. Sci Immunol. 2021 08 19; 6(62).
Score: 0.060
-
Neutralizing type-I interferon autoantibodies are associated with delayed viral clearance and intensive care unit admission in patients with COVID-19. Immunol Cell Biol. 2021 10; 99(9):917-921.
Score: 0.060
-
Association of rare predicted loss-of-function variants of influenza-related type I IFN genes with critical COVID-19 pneumonia. J Clin Invest. 2021 08 02; 131(15).
Score: 0.060
-
Harnessing Type I IFN Immunity Against SARS-CoV-2 with Early Administration of IFN-ß. J Clin Immunol. 2021 10; 41(7):1425-1442.
Score: 0.059
-
Life-Threatening COVID-19: Defective Interferons Unleash Excessive Inflammation. Med (N Y). 2020 Dec 18; 1(1):14-20.
Score: 0.057
-
Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020 10 23; 370(6515).
Score: 0.057